Steven Gelone
About Steven Gelone
Steven Gelone Board Member at Nabriva Therapeutics
Steven Gelone joined Nabriva Therapeutics in December 2014. Throughout his tenure, he served as President and Chief Operating Officer until January 2023. In his role at Nabriva Therapeutics, Gelone was involved in all stages of drug development and commercialization. His extensive experience in the pharmaceutical industry has made a significant impact on the company's growth and progress.
Steven Gelone Education and Expertise
Steven Gelone holds a Bachelor of Sciences and a Doctorate in Pharmacy degree from Temple University in Philadelphia. His academic background in pharmacy has provided a solid foundation for his career in drug development and commercialization. Gelone's education has equipped him with the knowledge and skills necessary to excel in various leadership positions in the pharmaceutical industry.
Steven Gelone Career at Spark Therapeutics
Steven Gelone served as the Head of Clinical Research and Development at Spark Therapeutics, Inc., a subsidiary of Roche Holdings AG. In this role, he was responsible for overseeing clinical research and development activities aimed at advancing the company's therapeutic pipeline. Gelone's contributions at Spark Therapeutics played a key role in the development of innovative treatments.
Steven Gelone Leadership Role at ViroPharma Inc.
At ViroPharma Inc., now a part of Takeda, Steven Gelone served as the Vice President of Development. During his tenure, he managed development operations and was instrumental in advancing the company's drug development initiatives. His leadership at ViroPharma contributed to the successful progression of various clinical programs.
Steven Gelone Professional Experience in Pharmaceutical Industry
Steven Gelone has held various leadership positions in the pharmaceutical industry, including roles with GSK and Vicuron Pharmaceuticals. Additionally, he has been associated with Temple University Schools of Pharmacy and Medicine. His diverse experience across different organizations highlights his expertise in drug development and commercialization, making him a valued leader in the field.